[Amodiaquine-induced agranulocytosis in malaria prevention: demonstration of an amodiaquine-induced cytotoxic antibody against granulocytes].
A patient is presented who developed agranulocytosis while taking amodiaquine for suppressive therapy of malaria. An amodiaquine-dependent granulocytotoxic antibody could be demonstrated in the patient's serum on day 1 after stopping amodiaquine medication. Granulocyte transfusion was ineffective on days 6 and 7, possibly due to the slow elimination of the drug.
D000293:Adolescent; D000373:Agglutinins / Q000032:analysis*; D000380:Agranulocytosis / Q000139:chemically induced* / Q000628:therapy; D000655:Amodiaquine / Q000009:adverse effects*; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects; D001803:Blood Transfusion; D005260:Female; D006098:Granulocytes / Q000276:immunology* / Q000637:transplantation; D006801:Humans; D008288:Malaria / Q000517:prevention & control*
D000373:Agglutinins; D000655:Amodiaquine
Amodiaquin-induzierte Agranulozytose bei Malariaprophylaxe: Nachweis eines amodiaquin-abhängigen zytotoxischen Antikörpers gegen Granulozyten.